Spruce Biosciences Inc (NAS:SPRB)
$ 0.4037 0.0082 (2.07%) Market Cap: 16.34 Mil Enterprise Value: -40.49 Mil PE Ratio: 0 PB Ratio: 0.32 GF Score: 32/100

Spruce Biosciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 09:00PM GMT
Release Date Price: $1.8
Jennifer Sadeghi
H.C. Wainwright & Co. - Analyst

Good afternoon, everyone, and welcome to H.C. Wainwright's 24th Annual Global Investment Conference. I'm Jennifer Sadeghi, an associate at H.C. Wainwright. And I'd like to introduce CFO Samir Gharib of Spruce Biosciences.

Spruce is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders. Samir?

Samir Gharib
Spruce Biosciences, Inc. - President, CFO

Great. Thank you, Jennifer. It's a pleasure to be here today, and it's a pleasure to provide a summary over Spruce Biosciences. As Jennifer noted, we're a late-stage company focused on the development and commercialization of novel therapies for rare endocrine disorders with significant unmet medical need.

Now, over the course of today's presentation, I do plan to make some forward-looking statements that are based on the beliefs and assumptions of management. I'd refer you to our filings with the SEC for more information around the risks and uncertainties regarding investment

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot